Cargando…
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM’s Law
Eroom’s law (Moore’s law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer...
Autor principal: | Van Norman, Gail A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058942/ https://www.ncbi.nlm.nih.gov/pubmed/30062175 http://dx.doi.org/10.1016/j.jacbts.2017.09.002 |
Ejemplares similares
-
Broadview Ventures: Investing in the Future of Cardiovascular Technology
por: Colecchi, Christopher, et al.
Publicado: (2016) -
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
por: Van Norman, Gail A.
Publicado: (2018) -
Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies
por: Van Norman, Gail A.
Publicado: (2018) -
Expanded Patient Access to Investigational New Devices: Review of Emergency and Nonemergency Expanded Use, Custom, and 3D-Printed Devices
por: Van Norman, Gail A.
Publicado: (2018) -
Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)